You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020311019
Dec 20204206
Jan 20212802
Feb 20212402
Mar 20214009
Apr 20215205
May 20212409
Jun 2021006
Jul 2021005
Aug 2021003
Sep 2021003
Oct 202124027
Nov 202126026
Dec 20212009
Jan 202248013
Feb 20223804
Mar 20224204
Apr 20224605
May 20223602
Jun 20223406
Jul 20228401
Aug 20221606
Sep 20223608
Oct 20221803
Nov 20222203
Dec 20221001
Jan 20231200
Feb 20232600
Mar 20231004
Apr 202310010
May 2023600
Jun 2023800
Jul 20231102
Aug 2023801
Sep 2023400
Oct 20232004
Nov 20231401
Dec 20232001
Jan 2024800
Feb 20241800
Mar 20242401
Apr 20244002
May 20243601
Jun 20241600
Jul 20241301
Aug 20241404
Sep 20241403
Oct 20242406
Nov 2024403
Dec 20242606
Jan 2025803
Feb 2025402
Mar 2025003
Apr 2025007
May 2025002
Jun 2025005
Total14190259